Trial Profile
Interest of Denosumab Treatment in Osteoporosis Associated to Systemic Mastocytosis
Status:
Active, no longer recruiting
Phase of Trial:
Phase III
Latest Information Update: 29 Sep 2022
Price :
$35
*
At a glance
- Drugs Denosumab (Primary)
- Indications Osteoporosis
- Focus Therapeutic Use
- Acronyms DenosuMast
- 13 Apr 2021 Planned End Date changed from 30 Mar 2024 to 1 Nov 2023.
- 13 Apr 2021 Planned primary completion date changed from 30 Mar 2024 to 1 Nov 2023.
- 13 Apr 2021 Status changed from recruiting to active, no longer recruiting.